First-line treatment of advanced non-small cell lung cancer with egfr exon 20 insertion mutations

By combining bispecific anti-EGFR/c-Met antibodies with chemotherapy, especially pemetrexed and carboplatin, the poor treatment outcomes in NSCLC patients with EGFR exon 20 insertion mutations were addressed, significantly prolonging median progression-free survival and overall survival, and achieving significant clinical response.

CN122459339APending Publication Date: 2026-07-24JANSSEN BIOTECH INC
View PDF 21 Cites 0 Cited by

Patent Information

Application Number
CN202480078184.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-03-13
Filing Date
2024-10-11
Publication Date
2026-07-24

AI Technical Summary

Technical Problem

Current treatment options are ineffective for patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, and the lack of effective targeted therapies results in short median progression-free survival (PFS) and overall survival (OS).

Method used

Combination therapy, including the administration of a therapeutically effective dose of bispecific anti-EGFR/c-Met antibody and chemotherapy, specifically the combination of pemetrexed and carboplatin, is used for treatment-naïve NSCLC patients with EGFR exon 20 insertion mutations.

Benefits of technology

It significantly improved median progression-free survival (PFS) and overall survival (OS), and achieved a duration of at least 9 months in partial or better responses, with some patients achieving progression-free status after 11 months.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The present disclosure provides methods for treating EGFR-positive non-small cell lung cancer (NSCLC) in a treatment-naive subject.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Engineered heterodimeric protein domains

    US20070287170A1

  • Production of Bispecific Antibodies

    US20090182127A1

  • Methods for Producing Polypeptides by Regulating Polypeptide Association

    US20100015133A1

  • Multi-Layer Film Comprising a Barrier Layer and an Antistatic Layer

    US20100028637A1

  • Method for Making Heteromultimeric Molecules

    US20110123532A1